CFDB - Cystic Fibrosis DataBase

Welcome in CFDB (Cystic Fibrosis DataBase)!

This is a web-based, free access tool for health care professionals, researchers and students to evaluate in real time what are the current evidences about clinical efficacy of interventions in CF.

You'll find more than 1,500 studies divided in 8 sections, including Cochrane reviews, Cochrane protocols, DARE, HTA and Economic reviews, published RCT, published non-RCT, congress abstracts and ongoing trials.

Objective of CFDB (Cystic Fibrosis DataBase)

CFDB is a database and was ideated to classify clinical studies to get answers to specific questions:

  • which interventions are effective, in which groups of CF patients and for which outcomes?
  • to what extent do the results of the literature allow to make decisions for specific clinical issues? What issues need to be studied further?

This tool may help clinicians, researchers, students to have a faster updated view of clinical research in CF by using queries on the main topics in CF care. It could also be helpful to anyone going to design new studies, as it provides a concise description of what is currently known and what issues, on the contrast, need additional research.

Latest articles

Dornase alfa for cystic fibrosis

Cochrane Database of Systematic Reviews - Cochrane Review

Details
  • 2018
  • Yang Connie

Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis

Cochrane Database of Systematic Reviews - Cochrane Review

Details
  • 2018
  • de Vries JJV

Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis

Cochrane Database of Systematic Reviews - Cochrane Review

Details
  • 2018
  • Southern KW

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis

Cochrane Database of Systematic Reviews - Cochrane Protocol (ongoing review)

Details
  • 2018
  • Nazareth D

Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.

primary studies published RCT

Details
  • 2018
  • Dezube R

Phase 2 initial results evaluating PTI-428, a novel CFTR amplifier, in patients with cystic fibrosis

primary studies congress abstract

Details
  • 2018
  • Flume P

A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del - Phase 2 - Recruiting

ongoing trials trial from www.clinicaltrials.gov

Details
  • 2018
  • Vertex Pharmaceuticals Incorporated